Elevated monoamine oxidase A binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms

Neuropsychopharmacology

Volumn 39, Issue 4, 2014, Pages 973-980

  Chiuccariello, Lina ^a   Houle, Sylvain ^a   Miler, Laura ^a   Cooke, Robert G ^a   Rusjan, Pablo M ^a   Rajkowska, Grazyna ^b   Levitan, Robert D ^a   Kish, Stephen J ^a   Kolla, Nathan J ^a   Ou, Xiaoming ^b   Wilson, Alan A ^a   Meyer, Jeffrey H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; major depressive disorder; monoamine oxidase; oxidative stress; serotonin

Indexed keywords

ADULT; CARBON RADIOISOTOPES; CEREBRAL CORTEX; DEPRESSIVE DISORDER, MAJOR; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HARMINE; HUMANS; HYPERPHAGIA; MAGNETIC RESONANCE IMAGING; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84894047457     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.297     Document Type: Article

References (48)

1. Bacher I, Houle S, Xu X, Zawertailo L, Soliman A, Wilson AA et al (2011). Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch General Psychiatry 68: 817-826.
2. Barton DA, Esler MD, Dawood T, Lambert EA, Haikerwal D, Brenchley C et al (2008). Elevated brain serotonin turnover in patients with depression: effect of genotype and therapy. Arch General Psychiatry 65: 38-46.
3. Dunjic-Kostic B, Ivkovic M, Radonjic NV, Petronijevic ND, Pantovic M, Damjanovic A et al (2012). Melancholic and atypical major depression-Connection between cytokines, psychopathology and treatment. Prog Neuropsychopharmacol Biol Psychiatry 43C: 1-6.
4. Filipenko ML, Beilina AG, Alekseyenko OV, Dolgov VV, Kudryavtseva NN (2002). Repeated experience of social defeats increases serotonin transporter and monoamine oxidase A mRNA levels in raphe nuclei of male mice. Neurosci Lett 321: 25-28.
5. Fitzgerald JC, Ufer C, De Girolamo LA, Kuhn H, Billett EE (2007). Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J Neurochem 103: 2189-2199.
6. Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C et al (1996). Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA 93: 14065-14069.
7. Freis ED (1954). Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med 251: 1006-1008.
8. Ginovart N, Meyer JH, Boovariwala A, Hussey D, Rabiner EA, Houle S et al (2006). Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain. J Cereb Blood Flow Metab 26: 330-344.
9. Gold PW, Chrousos GP (2002). Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol Psychiatry 7: 254-275.
10. Grunewald M, Johnson S, Lu D, Wang Z, Lomberk G, Albert PR et al (2012). Mechanistic role for a novel glucocorticoid-KLF11 (TIEG2) protein pathway in stress-induced monoamine oxidase A expression. J Biol Chem 287: 24195-24206.
11. Harlan J, Chen Y, Gubbins E, Mueller R, Roch JM, Walter K et al (2006). Variants in Apaf-1 segregating with major depression promote apoptosome function. Mol Psychiatry 11: 76-85.
12. Hovatta I, Tennant RS, Helton R, Marr RA, Singer O, Redwine JM et al (2005). Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 438: 662-666.
13. Johnson S, Stockmeier CA, Meyer JH, Austin MC, Albert PR, Wang J et al (2011). The reduction of R1, a novel repressor protein for monoamine oxidase a, in major depressive disorder. Neuropsychopharmacology 36: 2139-2148.
14. Kajimura N, Uchiyama M, Takayama Y, Uchida S, Uema T, Kato M et al (1999). Activity of midbrain reticular formation and neocortex during the progression of human non-rapid eye movement sleep. J Neurosci 19: 10065-10073.
15. Karlovic D, Serretti A, Vrkic N, Martinac M, Marcinko D (2012). Serum concentrations of CRP, IL-6, TNF-alpha and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry research 198: 74-80.
16. Liotti M, Mayberg HS, McGinnis S, Brannan SL, Jerabek P (2002). Unmasking disease-specific cerebral blood flow abnormalities: mood challenge in patients with remitted unipolar depression. Am J Psychiatry 159: 1830-1840.
17. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O (1994). Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord 32: 169-177.
18. Lowell BB, Shulman GI (2005). Mitochondrial dysfunction and type 2 diabetes. Science 307: 384-387.
19. McGrath PJ, Stewart JW, Nunes EV, Ocepek-Welikson K, Rabkin JG, Quitkin FM et al (1993). A double-blind crossover trial of imipramine and phenelzine for outpatients with treatmentrefractory depression. Am J Psychiatry 150: 118-123.
20. Meyer JH (2012). Neuroimaging markers of cellular function in major depressive disorder: implications for therapeutics, personalized medicine, and prevention. Clin Pharmacol Ther 91: 201-214.
21. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A et al (2006). Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch General Psychiatry 63: 1209-1216.
22. Meyer JH, Wilson AA, Sagrati S, Miler L, Rusjan P, Bloomfield PM et al (2009). Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch General Psychiatry 66: 1304-1312.
23. Nelson DL, Herbet A, Glowinski J, Hamon M (1979). [3H]Harmaline as a specific ligand of MAO A-II. Measurement of the turnover rates of MAO A during ontogenesis in the rat brain. J Neurochem 32: 1829-1836.
24. O'Doherty J, Dayan P, Schultz J, Deichmann R, Friston K, Dolan RJ (2004). Dissociable roles of ventral and dorsal striatum in instrumental conditioning. Science 304: 452-454.
25. Ou XM, Chen K, Shih JC (2006a). Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J Biol Chem 281: 21512-21525.
26. Ou XM, Chen K, Shih JC (2006b). Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 103: 10923-10928.
27. Patti ME, Corvera S (2010). The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev 31: 364-395.
28. Posternak MA, Zimmerman M (2001). Symptoms of atypical depression. Psychiatry Res 104: 175-181.
29. Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek- Welikson K et al (1993). Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl 21: 30-34.
30. Rajkowska G, Goldman-Rakic PS (1995a). Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria. Cereb Cortex 5: 307-322.
31. Rajkowska G, Goldman-Rakic PS (1995b). Cytoarchitectonic definition of prefrontal areas in the normal human cortex: II. Variability in locations of areas 9 and 46 and relationship to the Talairach Coordinate System. Cereb Cortex 5: 323-337.
32. Rajkowska G, Stockmeier CA (2013). Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 14: 1225-1236.
33. Ressler KJ, Mayberg HS (2007). Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 10: 1116-1124.
34. Rusjan P, Mamo D, Ginovart N, Hussey D, Vitcu I, Yasuno F et al (2006). An automated method for the extraction of regional data from PET images. Psychiatry Res 147: 79-89.
35. Sacher J, Wilson AA, Houle S, Rusjan P, Hassan S, Bloomfield PM et al (2010). Elevated brain monoamine oxidase A binding in the early postpartum period. Arch General Psychiatry 67: 468-474.
36. Salim S, Asghar M, Chugh G, Taneja M, Xia Z, Saha K (2010). Oxidative stress: a potential recipe for anxiety, hypertension and insulin resistance. Brain Res 1359: 178-185.
37. Saura J, Kettler R, Da Prada M, Richards JG (1992). Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19- 6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 12: 1977-1999.
38. Schmidt HD, Shelton RC, Duman RS (2011). Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology 36: 2375-2394.
39. Slotkin TA, Seidler FJ, Ritchie JC (1998). Effects of aging and glucocorticoid treatment on monoamine oxidase subtypes in rat cerebral cortex: therapeutic implications. Brain Res Bull 47: 345-348.
40. Sullivan PF, Kessler RC, Kendler KS (1998). Latent class analysis of lifetime depressive symptoms in the national comorbidity survey. Am J Psychiatry 155: 1398-1406.
41. Thalmeier A, Dickmann M, Giegling I, Schneider B, M Hartmann A, Maurer K et al (2008). Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. Int J Neuropsychopharmacol 11: 217-228.
42. Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ (1992). Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 53: 5-11.
43. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163: 28-40.
44. Uylings HB, Sanz-Arigita EJ, de Vos K, Pool CW, Evers P, Rajkowska G (2010). 3-D cytoarchitectonic parcellation of human orbitofrontal cortex correlation with postmortem MRI. Psychiatry Res 183: 1-20.
45. Verhoeff NP, Christensen BK, Hussey D, Lee M, Papatheodorou G, Kopala L et al (2003). Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol Biochem Behav 74: 425-432.
46. WHO (2008): The Global Burden of Disease: 2004 UpdateWorld Health Organization
47. Youdim MB, Edmondson D, Tipton KF (2006). The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7: 295-309.
48. Young SN, Smith SE, Pihl RO, Ervin FR (1985). Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl) 87: 173-177.